| Literature DB >> 29359407 |
Maureen Bardet1, Adeline Unterreiner1, Claire Malinverni1, Frédérique Lafossas1, Corinne Vedrine1, Danielle Boesch1, Yeter Kolb1, Daniel Kaiser1, Anton Glück1, Martin A Schneider1, Andreas Katopodis1, Martin Renatus1, Oliver Simic1, Achim Schlapbach1, Jean Quancard1, Catherine H Régnier1, Guido Bold1, Carole Pissot-Soldermann1, José M Carballido1, Jiri Kovarik1, Thomas Calzascia1, Frédéric Bornancin1.
Abstract
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is essential for immune responses triggered by antigen receptors but the contribution of its paracaspase activity is not fully understood. Here, we studied how MALT1 proteolytic function regulates T-cell activation and fate after engagement of the T-cell receptor pathway. We show that MLT-827, a potent and selective MALT1 paracaspase inhibitor, does not prevent the initial phase of T-cell activation, in contrast to the pan-protein kinase C inhibitor AEB071. However, MLT-827 strongly impacted cell expansion after activation. We demonstrate this is the consequence of profound inhibition of IL-2 production as well as reduced expression of the IL-2 receptor alpha subunit (CD25), resulting from defective canonical NF-κB activation and accelerated mRNA turnover mechanisms. Accordingly, MLT-827 revealed a unique transcriptional fingerprint of MALT1 protease activity, providing evidence for broad control of T-cell signaling pathways. Altogether, this first report with a potent and selective inhibitor elucidates how MALT1 paracaspase activity integrates several T-cell activation pathways and indirectly controls gamma-chain receptor dependent survival, to impact on T-cell expansion.Entities:
Keywords: Interleukin‐2; MALT1 paracaspase; NF‐kappaB; T‐cell receptor; T‐cell survival; protease inhibitor; signal transduction
Mesh:
Substances:
Year: 2017 PMID: 29359407 DOI: 10.1111/imcb.1018
Source DB: PubMed Journal: Immunol Cell Biol ISSN: 0818-9641 Impact factor: 5.126